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Abstract
Background: We have previously demonstrated that both canine and human OSA cell lines, as well as 8 fresh
canine OSA tumor samples, exhibit constitutive phosphorylation of STAT3, and that this correlates with enhanced
expression of matrix metalloproteinase-2 (MMP2). While multiple signal transduction pathways can result in
phosphorylation of STAT3, stimulation of the cytokine receptor gp130 through either IL-6 or Oncostatin M (OSM) is
the most common mechanism through which STAT3 is activated. The purpose of this study was to evaluate the
role of IL-6 and OSM stimulation on both canine and human OSA cell lines to begin to determine the role of
these cytokines in the biology of OSA.
Methods: RT-PCR and Western blotting were used to interrogate the consequences of OSM and IL-6 stimulation of
OSA cell lines. OSA cells were stimulated with OSM and/or hepatocyte growth factor (HGF) and the effects on
MMP2 activity (gel zymography), proliferation (CyQUANT), invasion (Matrigel transwell assay), and VEGF production
(Western blotting, ELISA) were assessed. The small molecule STAT3 inhibitor LLL3 was used to investigate the
impact of STAT3 inhibition following OSM stimulation of OSA cells.
Results: Our data demonstrate that the OSM receptor (OSMR), but not IL-6 or its receptor, is expressed by all
human and canine OSA cell lines and canine OSA tumor samples; additionally, OSM expression was noted in all
tumor samples. Treatment of OSA cell lines with OSM induced phosphorylation of STAT3, Src, and JAK2. OSM
stimulation also resulted in a dose dependent increase in MMP2 activity and VEGF expression that was markedly
reduced following treatment with the small molecule STAT3 inhibitor LLL3. Lastly, OSM stimulation of OSA cell
lines enhanced invasion through Matrigel, particularly in the presence of rhHGF. In contrast, both OSM and HGF
stimulation of OSA cell lines did not alter their proliferative capacity.
Conclusions: These data indicate OSM stimulation of human and canine OSA cells induces STAT3 activation,
thereby enhancing the expression/activation of MMP2 and VEGF, ultimately promoting invasive behavior
and tumor angiogenesis. As such, OSM and its receptor may represent a novel target for therapeutic
intervention in OSA.
Background
Osteosarcoma (OSA) is the most common malignant
bone tumor in humans and dogs, although the incidence
of disease in the dog population is approximately ten
times higher than in people [1,2]. OSA in both species
shares many features including the presence of micro-
scopic metastatic disease at diagnosis, the development
of chemotherapy resistant metastases, and dysregulation
of several key cellular proteins including Met, ezrin and
STAT3 [2-6]. Despite aggressive treatment including
surgery and chemotherapy, little improvement in survi-
val times has been achieved in either dogs or people
over the past 15 years even with significant efforts direc-
ted at the incorporation of novel therapeutic approaches
[7-9]. As such, the identification of key factors that reg-
ulate the aggressive biologic behavior of OSA, particu-
larly with respect to metastasis, will be necessary if
significant improvements in therapeutic outcome are to
occur.
Oncostatin M (OSM) is a member of the IL-6 cyto-
kine family produced by inflammatory cells and some
tumor cells including primary human osteoblasts and
* Correspondence: Cheryl.London@cvm.osu.edu
1Department of Veterinary Biosciences, The Ohio State University, Columbus,
OH 43210, USA
Full list of author information is available at the end of the article
Fossey et al. BMC Cancer 2011, 11:125
http://www.biomedcentral.com/1471-2407/11/125
© 2011 Fossey et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.the human OSA cell line MG-63 [10,11]. OSM stimula-
tion of cells induces diverse functions across a variety of
tissue types and cell lines such as modulation of growth
and differentiation, inflammation, remodeling of extra-
cellular matrix, and enhancement of metastatic capacity
[11-14], however the exact role that this cytokine plays
in bone biology has not yet been clearly defined [10,15].
OSM binds its receptor, oncostatin M receptor
(OSMR), which exists as part of a heterodimer with the
gp130 signal transducer, promoting reciprocal phos-
phorylation and activation of members of the Janus
kinase family (JAK). Additionally, evidence suggests that
O S Ma l s oa c t st h r o u g ht h el e u k e m i ai n h i b i t o r yf a c t o r
receptor (LIFR) and gp130 [16] with activation of DNA
binding activity of STAT1, STAT3, and STAT5B [17].
Indeed, gp130 signaling cytokines such as OSM have
been shown to be produced by mouse osteoblasts and
osteocytes with differing effects through these receptors
on osteoblast and osteoclast differentiation and activa-
tion [18-20]. Involvement of OSMR in bone biology was
demonstrated by the osteopetrotic phenotype of OSMR-
deficient mice [20]. The gp130 pathway has been shown
to have multiple roles in bone growth, resorption, and
formation thus making signaling through this pathway
an interesting new area of study in bone biology and
carcinogenesis [18].
Following OSM binding to OSMR and gp130, JAK2 is
phosphorylated, which in turn phosphorylates STAT3
permitting nuclear translocation and modulation of gene
expression [11,21,22]. Several transcriptional targets of
STAT3 are important contributors to tumor biology and
activation of STAT3 by gp130-mediated mechanisms is
known to be oncogenic [23]. STAT3 has been impli-
cated as being a central regulator of tumor progression
through its transcriptional upregulation of VEGF, Mcl-1,
and survivin, among others [24,25]. Additionally, mem-
bers of the Src family of tyrosine kinases have been
shown to be associated with and be activated through
cytokine binding to gp130 in cancer cells [26,27]. Our
previous work demonstrated that inhibition of STAT3
function in OSA cell lines using small molecule inhibi-
tors downregulated MMP2 and VEGF expression and
induced apoptosis suggesting that STAT3 activation
may be an important regulator of the aggressive biologic
behavior of OSA [6]. In support of this notion, a recent
study demonstrated that human OSA patients whose
tumors express high levels of phospho-STAT3 had a
worse prognosis [28,29]. Lastly, expression profiling of
pediatric OSA revealed that tumors with a poorer prog-
nosis were associated with greater expression of genes
enhancing cell migration and remodeling, many of
which are transcriptionally regulated by STAT3 [30]. As
such, the purpose of the following study was to explore
the impact of OSM and IL-6 stimulation on OSA cell
lines to begin to assess the role of the gp130 signaling
pathway in OSA cell biology.
Methods
Cell Lines and Reagents
Canine OSA cell lines, OSA 8 and 16 were provided by Dr.
Jaime Modiano (University of Minnesota, Minneapolis,
MN) [6]. The canine D17 OSA cell line and human OSA
cell lines U2OS and SJSA were purchased from American
Type Cell Culture Collection (ATCC). Cell line authentica-
tion of human OSA cell lines SJSA and U2OS was recently
completed by The Ohio State University Comprehensive
Cancer Center Molecular Cytogenetics Shared Resource
through karyotype analysis and comparison to that of the
cell lines at ATCC. The canine lines and human line SJSA
were maintained in RPMI-1640 supplemented with 10%
fetal bovine serum, non-essential amino acids, sodium pyr-
uvate, penicillin, streptomycin, L-glutamine, and HEPES
(4-(2-hydroxethyl)-1-piperazineethanesulfonic acid) at
35°C, supplemented with 5% CO2. The U2OS cell line was
cultured in McCoy’s medium with 10% FBS and the same
supplements as listed for the canine lines. The normal
canine osteoblasts were obtained from Cell Applications
(San Diego, CA) and maintained in Canine Osteoblast
Growth Medium with 10% FBS. Human spleen total RNA
was purchased from Ambion Biosystems (Austin, TX). The
canine OSA tumor and normal spleen samples were
obtained from dogs treated at The Ohio State University
College of Veterinary Medical Center in compliance with
established hospital policies regarding sample collection as
part of the Biospecimen Repository. Collection procedures
by the Biospecimen Repository are approved by the OSU
IACUC (2010A0015, Canine Specimen Collection and
Banking). Fresh tissue samples were immediately flash fro-
zen in liquid nitrogen and stored in The Ohio State Uni-
versity College of Veterinary Medicine Biospecimen
Repository. The tumors were evaluated and confirmed as
OSA by board certified veterinary pathologists at The Ohio
State University College of Veterinary Medicine.
RT-PCR
RNA was extracted from untreated canine and human
O S Ac e l l sa n dp u l v e r i z e df r e s hf r o z e nc a n i n eO S A
tumor samples using TRIzol reagent (Invitrogen, Carls-
bad, CA) according to the manufacturer’si n s t r u c t i o n s .
To generate cDNA, 2 μgo ft o t a lR N Aa n dt h eM - M L V
reverse transcriptase kit (Invitrogen, Carlsbad, CA) were
used according to the manufacturer’si n s t r u c t i o n s .N e x t ,
1/20 of the resultant cDNA was used for each PCR
reaction in a total volume of 25 μl. Primers were
designed and utilized for canine and human interleukin-
6, interleukin-6 receptor, oncostatin M, oncostatin M
receptor, gp130, and GAPDH (Table 1). Annealing tem-
peratures for these reactions are listed in Table 1. All
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Page 2 of 10PCR products were run on a 2% agarose gel with ethi-
dium bromide and visualized using the Alpha Imager
system (Alpha Innotech Corp, San Leandro, CA).
Western Blotting
Protein lysates were prepared and quantified, separated
by SDS-PAGE, and Western blotting was performed as
described previously [6] on 2 × 10
6 OSA cells after sti-
mulation with either PBS or recombinant human oncos-
tatin M (rhOSM, 50 or 100 ng/mL; R&D Systems,
Minneapolis, MN) or recombinant canine interleukin-6
(rcIL-6) (30 ng/mL; R&D Systems, Minneapolis, MN)
for 0, 5, 10, or 30 minutes. Additionally, human OSA
cell line SJSA was stimulated with either PBS, 50 or 100
ng/mL rhOSM, or 100 ng/mL rhOSM and the small
molecule STAT3 inhibitor LLL3 [6] at 40 μMf o r7 2
hours prior to collecting cells and preparing protein
lysates that were separated by SDS-PAGE. The mem-
branes were then incubated overnight with anti-
p-STAT3 (Y705, Cell Signaling Technology, Danvers,
MA), anti-p-JAK2 (Y1007/1008, Millipore, Temecula,
CA), anti-VEGF (Santa Cruz Biotechnology, Santa Cruz,
CA), or anti-p-Src (Y418, Invitrogen, Carlsbad, CA)
after which they were incubated with appropriate horse-
radish peroxidase linked secondary antibodies, washed,
and exposed to substrate (SuperSignal West Dura
Extended Duration Substrate, Pierce, Rockford, IL). Blots
were stripped, washed, and reprobed for b-actin (Santa
Cruz Biotechnology, Santa Cruz, CA), total STAT3 (Cell
Signaling Technology, Danvers, MA), total JAK2
(Cell Signaling Technology,D a n v e r s ,M A )o rt o t a lS r c
(Cell Signaling Technology, Danvers, MA). Images
shown are representative of all repeats of the experi-
ments. Experiments were repeated twice.
Immunoprecipitation
OSA cells (7 × 10
6) cells were serum starved for two hours
then treated with rhOSM (50 ng/mL) for 0 or 15 minutes.
Cells were collected and lysate prepared as described
previously [6]. The Rabbit TrueBlot™ kit (eBioscience,
San Diego, CA) was utilized to immunoprecipitate canine
gp130 using anti-gp130 antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA) according to manufacturer’s
instructions. Protein was separated by SDS-PAGE and
transferred to a PVDF membrane. Western blotting using
an anti-Src or anti-STAT3 antibody (Cell Signaling
Biotechnology, Danvers, MA) was performed after addi-
tion of the appropriate secondary antibody. The mem-
brane was stripped and reprobed for gp130 and b-actin
(Santa Cruz Biotechnology, Santa Cruz, CA).
CyQUANT
OSA cells (2 × 10
3 cells/well) were seeded in 96-well
plates overnight and incubated with PBS, 50, or 100 ng/
mL rhOSM for 72 hours. Each treatment group was
performed in four replicate wells. Prior to collection,
media was removed and the plates were frozen at -80°C
overnight before processing with the CyQUANT
® Cell
Proliferation Assay Kit (Molecular Probes, Eugene, OR)
according to manufacturer’s instructions and analyzed
as described previously [6].
Gel Zymography
Cells were plated as previously described [6] and treated
with PBS, 50, or 100 ng/mL rhOSM or 100 ng/mL
rhOSM and the small molecule STAT3 inhibitor LLL3
40 μM [6]. Separate experiments were conducted with
cells plated in a similar manner and treated with PBS,
rhOSM (50 ng/mL), rhHGF (50 ng/mL), or the two
together. Media was collected after 72 hours, processed,
and gel zymography performed as described previously
[6]. Images were scanned and analyzed using Image J.
Invasion Assays
Canine (OSA8) and human (SJSA) OSA cells were plated
in invasion assay experiments as described previously
Table 1 Primer pairs used for RT-PCR
Gene Primers (forward/reverse) Annealing Temp (°C)
Canine IL-6 (5’-gagattccaaggatgatg/gcctctttgctgtcttcaca-3’)5 5
Canine IL-6R (5’-gagatctgtgcagctcagcgactc/ctccactcacagaatacc-3’)5 5
Canine OSM (5’-gtccttggactcctgttcctg/cactcagcatctccaagtc-3’)5 5
Canine OSMR (5’-gtaaggtggaccgaggagatg/gagcaagccagtgtctctc-3’)5 5
Canine gp130 (5’-gaagcccagtccacc/ccttcatacaacgaatcc-3’)5 5
Canine GAPDH (5’-accacagtccatgccatcac/tccaccaccctgttgctgta-3’)5 5
Human IL-6 (5’-gctgctcctggtgttgcctg/ggttgttttctgccagtg-3’)5 5
Human IL-6R (5’-cagcagatgggctggcatgggaag/ccaagagcacagcctttgtc-3’)5 5
Human OSM (5’-gtaccgcgtgctccttgg/cggcctcgccatctgcagc-3’)6 0
Human OSMR (5’-gcaagtcaaggaaatgtcagtg/ccccaaggcagtgtccgtcc-3’)6 0
Human gp130 (5’-gaagcccaatccgccacataatttatc/cttcataggtgatcccacttg-3’)6 0
Human GAPDH (5’-gcgcctggtcaccagggctgc/gaatttgccatgggtggaatc-3’)6 0
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Page 3 of 10[ 3 1 ] .B r i e f l y ,c e l l sw e r ep l ated in the upper chamber in
serum-free media with rhOSM (50 ng/mL) for all treat-
ment groups. The lower chambers contained media with
10% fetal bovine serum alone (C10), C10 with rhOSM
(50 ng/mL), C10 with rhHGF (50 ng/mL), or C10 with
both cytokines at 50 ng/mL. Cells were incubated over-
night to allow invasion through the Matrigel layer. Inserts
were processed and cells counted as previously described
[31]. Treatments were run in quadruplicate and cells
from ten random fields from each replicate were counted.
VEGF ELISA
125,000 canine (OSA8) or human (SJSA) OSA cells were
plated in C10 media in a six well plate and cultured
overnight. The media was removed and cells incubated
for 24 hours in C1 media with PBS, OSM 50 or 100 ng/
mL, or OSM 100 ng/mL + LLL3 40 μM. Media was
removed and frozen at -80°C. VEGF expression was
determined using the DuoSet ELISA Development Sys-
tem for canine or human VEGF (R&D Systems, Minnea-
polis, MN) according to manufacturer’s instructions.
Statistical Methods
In the invasion assays, we computed the average cell
count per replicate and analyzed the means using a ran-
domized block ANOVA (blocked on plate). Prior to
analysis, the means were square root transformed in
order to better satisfy the normality and equal variance
assumptions of ANOVA. An overall F test of a differ-
ence in means across treatment groups was computed
and pairwise comparisons of the groups were performed
using Holm’s method to control type-I error [32]. All
experiments were performed two to three times. Statisti-
cal analysis of the VEGF ELISA data was performed
using the Student’s t-test. P values of less than or equal
to 0.05 were considered statistically significant.
Results
Oncostatin M Receptor and gp130 are expressed in
human and canine OSA cell lines
Expression of IL-6, IL-6 receptor, OSM, OSMR, and
gp130 was determined in three canine (OSA8, 16, and
D17) and two human (SJSA and U2OS) OSA cell lines
by RT-PCR (Figures 1a and 1b, respectively). All cell
lines expressed message for gp130 and OSMR; no
expression of OSM was detected. IL-6 expression was
variable and weak in canine OSA8 and D17 and human
SJSA cells and IL-6 receptor was weakly expressed in
canine OSA16 and human SJSA and U2OS cells. Given
the apparent lack of IL-6/IL-6R expression in the OSA
cells, we focused on OSM and its receptor in the fresh
frozen OSA tumor samples from canine patients. OSMR
expression was noted in all 8 canine tumor samples
evaluated as well as the normal canine osteoblasts while
OSM expression was detected in all samples although 2
of these were weak; normal canine osteoblasts did not
express OSM. (Figure 1c).
JAK2/STAT3 and Src phosphorylation is stimulated by
Oncostatin M in OSA cell lines
OSM is known to activate the OSMR/gp130 heterodimer
leading to phosphorylation of the JAK family kinases, in
particular JAK2. Canine (OSA8) and human (SJSA) OSA
cell lines were serum starved then stimulated with
rhOSM (50 ng/mL) for 0, 5, 10, or 30 minutes before col-
lecting cells for Western blotting (Figure 2). Basal levels
of phosphorylated JAK2 were very low in both cell lines,
however stimulation with OSM led to an immediate,
transient increase in phosphorylation in OSA8 and a
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GAPDH
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12345678
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Figure 1 Expression of OSM and IL-6 receptors in canine and
human OSA. RNA was collected from untreated A) canine (OSA8,
16, and D17) or B) human (SJSA and U2OS) OSA cell lines and RT-
PCR was performed for IL-6, IL-6 receptor, OSM, OSMR, gp130, and
GAPDH. C) RNA was collected from eight fresh frozen OSA tumors
from canine patients and normal canine osteoblasts (Nml K9 Ob)
and RT-PCR performed for OSM, OSMR, and GAPDH.
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Page 4 of 10more sustained, time dependent increase in SJSA. Basal
levels of STAT3 and Src phosphorylation were present as
described previously in the OSA cell lines [6]; however,
phosphorylation of both STAT3 and Src increased sub-
stantially within five minutes of OSM treatment. Levels
of total protein for STAT3, Src, and JAK2 remained lar-
gely unchanged during all time points.
JAK2/STAT3 phosphorylation is not stimulated by IL-6 in
canine OSA
Given the expression of mRNA for IL-6 receptor in
canine OSA cell line OSA16, we wanted to determine
whether stimulation with its ligand IL-6 would impact
JAK2 or STAT3 phosphorylation as had occurred with
OSM. Cells were serum starved then treated with rcIL-6
for 0, 5, 10, or 30 minutes before cells were collected
for Western blotting. JAK2 phosphorylation was not
present at baseline and stimulation with IL-6 did not
induce JAK2 phosphorylation (Figure 3). Basal STAT3
phosphorylation was present in OSA16 and this was not
altered following IL-6 stimulation. Levels of total
STAT3 and JAK2 proteins were not altered during all
time points evaluated.
Src and STAT3 are associated with gp130 in OSA cell lines
with or without Oncostatin M stimulation
Binding of OSM to its receptor and gp130 results in
recruitment of JAK2 to the receptor complex and subse-
quent recruitment and phosphorylation of STAT3. This
association likely explains the activation observed in
Figure 2, however the activation of Src after OSM binding
is not as clear. Multiple members of the Src family of tyro-
sine kinases were coprecipitated with gp130 in lysates
from multiple myeloma cells and stimulation with IL-6 led
to increased activity of these Src family kinases [26]. We
wanted to determine whether Src was associated with the
gp130 complex in OSA cells as well. Canine (OSA8) and
human (SJSA) OSA cell lines were serum starved for
2 hours then left untreated or treated for 15 minutes with
rhOSM (50 ng/mL). Lysates were collected and gp130 was
immunoprecipitated from the canine and human OSA cell
lines (Figure 4). Western blotting revealed that Src and
STAT3 were associated with gp130 in the presence or
absence of OSM indicating that these proteins are part of
the gp130 complex in these cell lines. The lack of b-actin
in the co-precipitates confirmed the specificity of the
immunoprecipitation experiment (Figure 4).
SJSA 
0’ 5’ 10’ 30’
rhOncostatin M
50ng/mL
pSTAT3
STAT3
pJAK2
JAK2
OSA8 
pSrc
Src
0’ 5’ 10’ 30’
rhOncostatin M
50ng/mL
pSTAT3
STAT3
pJAK2
JAK2
pSrc
Src
Figure 2 Activation of STAT3, JAK2, and Src in OSA cell lines
upon following stimulation with OSM. Canine (OSA8) or human
(SJSA) OSA cell lines were serum starved for two hours then
stimulated with rhOSM (50 ng/mL) for 0 (no OSM stimulation), 5, 10,
or 30 minutes. Protein lysates were generated and separated by
SDS-PAGE and Western blotting for pSTAT3 (Y705), total STAT3,
pJAK2 (Y1007/1008), total JAK2, pSrc (Y418), and total Src was
performed.
0’ 5’ 10’ 30’ rcIL6 30ng/mL
pSTAT3
STAT3
pJAK2
JAK2
OSA16 
Figure 3 Lack of IL-6 signaling in canine OSA. The canine OSA
cell line OSA16 was serum starved for two hours then stimulated
with rcIL6 (30 ng/mL) for 0, 5, 10, or 30 minutes. Protein lysates
were generated and separated by SDS-PAGE and Western blotting
for pSTAT3 (Y705), total STAT3, pJAK2 (Y1007/1008), and total JAK2
was performed.
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Page 5 of 10Oncostatin M stimulation does not alter the proliferation
of OSA cell lines
OSM is a cytokine with multiple, divergent effects on
cell proliferation differing among cell types and lines
with growth inhibition effects reported in melanoma
and glioma cells but stimulation of growth of Kaposi’s
sarcoma cells [11]. Canine (OSA8) and human (SJSA)
OSA cell lines were incubated with 0, 50, or 100 ng/mL
rhOSM for 72 hours and proliferation was assessed
using the CyQUANT assay. As shown in Figure 5, there
was no effect of OSM stimulation on OSA cell prolifera-
tion at either concentration.
Oncostatin M stimulation of OSA cell lines enhances
MMP2 and VEGF expression and tumor cell invasion
Previous work has shown that OSM promotes expression
of MMPs including MMP1 and MMP3 in astrocytes [33],
MMP1 and MMP9 in fibroblasts [33], and MMP1,
MMP3, and MMP13 in chondrocytes [34]. Indeed,
increased expression of MMP2 and MMP9 was linked to
increased invasive capability in human and canine OSA
[35,36]. We treated canine (OSA8) and human (SJSA)
OSA cell lines with 0, 50, or 100 ng/mL rhOSM or 100
ng/mL OSM and 40 μM of the small molecule STAT3
inhibitor LLL3. We have shown in previous work that
this STAT3 inhibitor down-regulates MMP2 expression
at 72 hours following exposure [6]. OSM stimulation
induced a dose dependent increase in MMP2 activity that
was abrogated in the presence of LLL3 suggesting that
the increase in MMP2 activity conferred by OSM stimu-
lation is due in part to STAT3 activation (Figure 6a).
To determine whether the effect of OSM on MMP2
expression was biologically relevant with respect to
tumor cell invasion, we cultured canine (OSA8) or
human (SJSA) OSA cells in inserts containing serum-
free media and rhOSM (50 ng/mL) overlying a Matrigel
substrate. These inserts were placed in wells containing
either media with 10% fetal bovine serum alone (C10),
C10 with rhOSM (50 ng/mL), C10 with rhHGF (50 ng/
mL), or C10 media with both cytokines together at
same concentrations (50 ng/mL). After 18 hours of
incubation, OSA cell lines treated with either cytokine
alone exhibited significantly enhanced invasion as com-
pared to media alone. (Figure 6b). Furthermore, invasion
of OSA cells treated with both rhOSM and rhHGF was
significantly greater than that observed with either
cytokine/growth factor alone. Upregulation of MMP2
activity was observed following treatment with rhOSM
alone, rhHGF alone and both OSM and HGF in combi-
nation (Figure 6c). Finally, stimulation of the human
O S Ac e l ll i n eS J S Aw i t hO S Ml e dt od o s ed e p e n d e n t
increases in VEGF protein expression that was largely
SJSA 
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gp130
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`-actin
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Figure 4 Src and STAT3 are associated with gp130 in human
and canine OSA cell lines. Canine (OSA8) or human (SJSA) OSA
cell lines were serum starved for two hours then left untreated or
stimulated with rhOSM (50 ng/mL) for 15 minutes. Protein lysates
were generated and immunoprecipitation performed for gp130.
Co-precipitated proteins were separated by SDS-PAGE and Western
blotting performed for total Src, total STAT3, gp130, or b-actin.
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Figure 5 OSM does not alter the proliferation of OSA cell lines.
Canine (OSA8) or human (SJSA) OSA cell lines were treated with 0,
50, or 100 ng/mL rhOSM for 72 hours in triplicate. Proliferation was
analyzed using the CyQUANT cell proliferation assay kit. Proliferation
values are listed as a percentage of PBS control and the bars
represent the standard error of the mean.
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Page 6 of 10abrogated by concurrent treatment with the small mole-
cule STAT3 inhibitor LLL3 (Figures 6d and 6e).
Discussion
The link between inflammation and carcinogenesis is
well known; experiments have implicated many compo-
nents of the inflammatory cascade such as prostaglandin
E2 and IL-6 as key players in tumor development,
growth, and metastasis [37,38]. These inflammatory
cytokines and growth factors, either generated by the
tumor cells themselves in an autocrine manner or
derived from inflammatory or stromal cells in the tumor
microenvironment, have received much attention as
potential targets for therapeutic intervention [37,39,40].
Indeed, these cytokines trigger the activation of many sig-
naling pathways known to contribute to tumorigenesis
and chemoresistance such as the JAK/STAT and Ras/
Raf/MAPK pathways [11]. We had previously shown that
STAT3 activation was present in a substantial number of
OSA cell lines and primary canine OSA tumor samples
and that inhibition of STAT3 using either a small mole-
cule inhibitor or siRNA resulted in death of OSA cells
in vitro [6]. The purpose of the following study was to
identify possible drivers of the observed STAT3 activation.
Figure 6 OSM stimulation enhances MMP2 and VEGF activity and OSA cell invasion. A) Canine (OSA8) or human (SJSA) OSA cells were
treated with 0, 50, or 100 ng/mL rhOSM or 100 ng/mL OSM in combination with the small molecule STAT3 inhibitor LLL3 (40 μM) for 72 hours.
Media was collected, processed, and gel zymography performed as described previously [6]. B) Canine (OSA8) and human (SJSA) OSA cells were
plated in serum free media with 50 ng/mL rhOSM in the upper wells of plates for invasion assays. Cells were incubated overnight to allow for
invasion through a layer of Matrigel. The lower chamber of each treatment group contained either 10% fetal bovine serum alone (C10), C10
media with rhOSM (50 ng/mL), C10 media with rhHGF (50 ng/mL), or C10 media with both cytokines at 50 ng/mL. Cells were counted in ten
random fields in quadruplicate replicates. The bars refer to the standard error of the mean. **p < 0.01; ***p < 0.001 C) Canine (OSA8) or human
(SJSA) OSA cells were treated with 0, 50 ng/mL rhOSM, 50 ng/mL rhHGF, or the two cytokines together at 50 ng/mL for 72 hours. Media was
collected, processed, and gel zymography performed as described previously. D) Canine (OSA8) and human (SJSA) OSA cells were left untreated
or incubated with 50 or 100 ng/mL rhOSM, or 100 ng/mL rhOSM + LLL3 40 μM for 24 hours. Media was collected and VEGF concentrations
determined by ELISA. E) Human (SJSA) OSA cells left untreated or incubated with 50 or 100 ng/mL rhOSM, or 100 ng/mL rhOSM + 40 μM LLL3
for 72 hours. Protein lysates were generated and separated by SDS-PAGE and Western blotting for VEGF and b-actin was performed.
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Page 7 of 10Our data demonstrate that OSM, a member of the IL-6
subfamily of cytokines, and components of the OSM sig-
naling pathway are expressed in OSA cell lines and
tumor samples, and that activation of the JAK/STAT3
pathway with OSM stimulation leads to increased pro-
duction of MMP2, VEGF, and enhanced tumor cell inva-
sion. These results suggest that this pathway may be
important in vivo for OSA cell metastasis by facilitating
the process of invasion and angiogenesis. Interestingly,
expression of IL-6 and IL-6R was either very low or
absent in the OSA cells and the cells did not respond to
stimulation with IL-6 indicating that this cytokine is
likely not an important contributor to OSA pathobiology.
OSM is known to affect a variety of biological pro-
cesses including cell growth and differentiation, hemato-
poiesis, and inflammation [11]. It has also been
implicated as having a role in bone remodeling [20,41]
in part through stimulating osteoblast differentiation
and activation. OSM can be expressed in the bone mar-
row compartment [42] and is secreted from activated
lymphocytes, monocytes, and neutrophils [11,43]. Inter-
estingly, breast cancer cells have been demonstrated to
stimulate neutrophils to produce the cytokine [43] and
experiments have shown that OSM is produced by mul-
tiple human osteoblast-like cell lines including the OSA
cell line MG-63 and mouse osteoblasts and osteocytes
[10,20]. Co-expression of OSM and its receptor was
noted in the fresh frozen tumor samples while only
OSM receptor was identified in the cell lines. Based on
these data, it is possible that the OSM found in the
tumor specimens is derived from local inflammatory or
stromal cells in the OSA tumor microenvironment inde-
pendent of or, as demonstrated with the breast cancer
cell lines, under the influence of the tumor cells.
OSM activates JAK2 and STAT3 upon binding to its
receptor in many cells including murine, rat, and
human osteoblastic cells and osteosarcoma cell lines
[21,22]. However, the role of this cytokine pathway in
OSA tumor cell survival and metastasis has not been
fully explored. Upon stimulation with OSM, we demon-
strated marked increases in JAK2, STAT3, and Src
phosphorylation in canine and human OSA cell lines.
This signaling enhanced the production of VEGF which
is consistent with activation of STAT3, as it could be
blocked by the small molecule STAT3 inhibitor LLL3
[6]. It has been shown that OSM stimulation enhances
VEGF expression in adipocytes [44] and that OSM sti-
mulates strong phospho-STAT3 (tyrosine 705) in nor-
mal and keloid fibroblasts [45]. Given that OSM is
present in all canine patient tumor samples, it is plausi-
ble to infer that OSM in the tumor microenvironment
in vivo likely enhances OSA basal Src and STAT3 acti-
vation and JAK2 phosphorylation. Indeed, the enhanced
phosphorylation of Src and STAT3 and co-localization
of Src and STAT3 with gp130 in the OSA cell lines fol-
lowing OSM stimulation suggest that a similar func-
tional and spacial relationship exists between STAT3
and Src as shown by Schaeffer et al in multiple myeloma
cells in which binding of IL-6 to gp130 led to activation
of the Src family kinase Hck [26].
OSM is known to confer multiple, often divergent
functions to various cell types including inhibition of
melanoma and astroglioma tumor cell growth [43,46]
and stimulation of proliferation of AIDS-related Kaposi’s
sarcoma cells and fibroblasts [47]. In OSA cells, OSM
has been shown to downregulate osteoblast markers and
induce glial fibrillary acidic protein [21], promote an
osteocyte-like differentiation [12], and sensitize rat OSA
cells to the antitumor effect of midostaurin [14]. How-
ever, our data indicate that treatment of canine and a
human OSA cell lines does not impact their prolifera-
tion or viability. Other studies have shown that OSM
h a sar o l ei nr e g u l a t i n gt h eM M P sa sp a r to fb o t h
wound healing and inflammation [11]. Enhanced MMP9
expression has been observed in astroglioma cell lines
following OSM exposure [46] and breast cancer cells
treated with OSM demonstrated increased VEGF pro-
duction associated with detachment and invasion [43].
OSM stimulation has been linked to VEGF upregulation
in normal adipocytes, liver, smooth muscle, and cardiac
myocytes [44,48-50]. Lastly, OSM stimulation of astro-
glioma cells led to increased STAT3-dependent VEGF
expression [51].
We observed increased MMP2 activity and VEGF
expression with OSM stimulation of OSA cell lines that
was partially abrogated by the small molecule STAT3
inhibitor, LLL3 [6]. Higher levels of VEGF expression in
human OSA tumors have been shown to correlate with
a significantly worse prognosis and the presence of lung
metastasis [52,53]. Higher VEGF expression also has
predictive value for survival of OSA patients [54]. With
respect to canine OSA, one study found that pretreat-
ment platelet-corrected serum VEGF levels correlated
significantly with DFI in dogs with OSA following
amputation and adjuvant chemotherapy [55]. Lastly,
higher levels of plasma VEGF were found in more
aggressive neoplasms in a survey of spontaneous canine
tumors including those of the bone [56]. These data
suggest that OSM stimulation of OSA cells may
enhance VEGF production, thereby promoting angio-
genesis, contributing to the metastatic cascade. Our data
showed that OSM stimulation of OSA lines significantly
enhanced the invasive behavior of OSA cells and that
this was augmented in the presence of HGF. However,
we have previously demonstrated that HGF stimulation
of OSA cells does not promote STAT3 phosphorylation
[31], and it is thus likely that HGF contributes to the
observed invasion through mechanisms other than
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be relatively ubiquitous in the tumor microenvironment,
it is possible they may work to promote early invasion
and metastasis of OSA cells in vivo.
Conclusions
Early microscopic metastasis is a frequent finding in
OSA and the treatment of this disease will depend in
part on identifying therapeutic targets to abrogate this
process. We have shown in previous work that STAT3
dysregulation is frequently found in canine and human
OSA cell lines and canine patient tumor samples. Our
data here indicate that JAK2 and STAT3 are activated
by the cytokine OSM and that this cytokine is present
in canine patient tumor samples. Although OSM has
various and at times contradictory functions in many
tumor types, in our cell lines OSM enhanced MMP2
and VEGF expression and function in part through
STAT3 activation, thereby promoting tumor cell inva-
sion. These results support the notion that OSM may
contribute to the invasive and metastatic nature of OSA
through activation of STAT3, and as such may represent
a viable pathway for therapeutic intervention.
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